Literature DB >> 30095514

Glenohumeral Osteoarthritis in the Young Patient.

Bryan M Saltzman1, Timothy S Leroux, Nikhil N Verma, Anthony A Romeo.   

Abstract

Glenohumeral osteoarthritis in the young patient (aged <60 years) is a difficult condition, given both age and functional demands. Primary osteoarthritis is the most common etiology in this patient demographic, but secondary causes include osteonecrosis, previous trauma (eg, fracture-dislocation), previous infection (eg, septic arthritis), previous capsulorrhaphy, previous arthroscopic surgery (eg, chondrolysis), and glenoid dysplasia. Nonsurgical modalities, including activity modification, pharmacotherapy, physical therapy, and intra-articular injections, are the mainstay of management; however, in young patients who have exhausted nonsurgical management, surgical options include arthroscopic débridement, humeral head replacement with or without glenoid treatment (ie, biologic glenoid resurfacing, glenoid reaming), and total or reverse total shoulder arthroplasty. Unfortunately, failure rates after surgical management are considerably higher in young patients compared with those observed in older, more sedentary patients. Here, we focus on the etiology, evaluation, and management of young patients with glenohumeral osteoarthritis, with a focus on clinical outcomes.

Entities:  

Mesh:

Year:  2018        PMID: 30095514     DOI: 10.5435/JAAOS-D-16-00657

Source DB:  PubMed          Journal:  J Am Acad Orthop Surg        ISSN: 1067-151X            Impact factor:   3.020


  9 in total

1.  Previous surgery for instability is a risk factor for a worse patient-reported outcome after anatomical shoulder arthroplasty for osteoarthritis: a Danish nationwide cohort study of 3,743 arthroplasties.

Authors:  Jeppe V Rasmussen; Bo S Olsen
Journal:  Acta Orthop       Date:  2022-06-21       Impact factor: 3.925

Review 2.  Shoulder Arthroplasty Options for Glenohumeral Osteoarthritis in Young and Active Patients (<60 Years Old): A Systematic Review.

Authors:  Hélder Fonte; Tiago Amorim-Barbosa; Sara Diniz; Luís Barros; Joaquim Ramos; Rui Claro
Journal:  J Shoulder Elb Arthroplast       Date:  2022-03-23

3.  Arthroscopic management of glenohumeral arthritis in the young patient does not negatively impact the outcome of subsequent anatomic shoulder arthroplasty.

Authors:  Corey J Schiffman; Anastasia J Whitson; Sagar S Chawla; Frederick A Matsen; Jason E Hsu
Journal:  Int Orthop       Date:  2021-07-13       Impact factor: 3.075

Review 4.  Pharmacological Treatment in the Management of Glenohumeral Osteoarthritis.

Authors:  Omar A Al-Mohrej; Carlos Prada; Timothy Leroux; Harsha Shanthanna; Moin Khan
Journal:  Drugs Aging       Date:  2022-01-19       Impact factor: 3.923

5.  Glenohumeral Osteoarthritis: The Role for Orthobiologic Therapies: Platelet-Rich Plasma and Cell Therapies.

Authors:  Luciano A Rossi; Nicolás S Piuzzi; Shane A Shapiro
Journal:  JBJS Rev       Date:  2020-02

6.  A humeral hemiarthroplasty with biologic resurfacing of the glenoid using an allo-Achilles tendon: two case reports.

Authors:  Ki-Yong Choi; Kyu-Hak Jung; Young-Kyu Kim; Young-Hyun Yoon
Journal:  Clin Shoulder Elb       Date:  2021-02-22

7.  Resurfacing hemiarthroplasty versus stemmed hemiarthroplasty for glenohumeral osteoarthritis: a meta-analysis.

Authors:  Baoliang Zhang; Guanghui Chen; Tianqi Fan; Zhongqiang Chen
Journal:  Arthroplasty       Date:  2020-09-01

8.  Humeral Head Resurfacing for Isolated Primary Humeral Osteoarthritis With a Large Chondral Defect.

Authors:  Benjamin Kerzner; Nabil Mehta; Zeeshan A Khan; João A Bonadiman; Dhanur Damodar; Suhas P Dasari; Luc M Fortier; Nikhil N Verma
Journal:  Arthrosc Tech       Date:  2022-06-14

9.  3-T T2 mapping magnetic resonance imaging for biochemical assessment of normal and damaged glenoid cartilage: a prospective arthroscopy-controlled study.

Authors:  Felix Wuennemann; Laurent Kintzelé; Alexander Braun; Felix Zeifang; Michael W Maier; Iris Burkholder; Marc-André Weber; Hans-Ulrich Kauczor; Christoph Rehnitz
Journal:  Sci Rep       Date:  2020-09-01       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.